

# T A B L E O F C O N T E N T S

<b>Chapter 1: What Is a CRA?</b> .....	<b>1</b>
The CRA—An Overview .....	1
The CRA Personality .....	3
CRA Tasks .....	5
Career Preparation .....	6
In the Future .....	9
Your Value .....	9
<b>Chapter 2: The History Behind the Regulations</b> .....	<b>11</b>
Regulation and Human Subject Protection Milestones .....	12
Summary .....	18
<b>Chapter 3: The Research Process</b> .....	<b>20</b>
Pre-clinical Research .....	20
The IND (Investigational New Drug) Application .....	25
Clinical Trials .....	27
Summary .....	33
<b>Chapter 4: Regulations and GCPs</b> .....	<b>35</b>
FDA Regulations for Clinical Trials .....	36
ICH Guidelines for Good Clinical Practice .....	36
FDA Guidelines and Information Sheets .....	37
FDA Compliance Program Guidance Manuals .....	37
NIH-Regulated Research .....	38
FDA Bioresearch Monitoring Program (BIMO) .....	38
Good Clinical Practice (GCP) .....	39
Contacting the FDA .....	39

<b>Chapter 5: Institutional Review Boards</b>	<b>42</b>
Types of IRBs	43
IRB Responsibilities	44
IRB Review of Proposed Research	47
IRB Membership	50
IRB Operations	50
Conflict of Interest	51
<b>Chapter 6: Informed Consent</b>	<b>52</b>
Monitoring Informed Consent	53
Basic Elements of Consent	54
Obtaining Informed Consent	56
The Consent Process	57
Exceptions from Consent	58
Conclusion	61
<b>Chapter 7: Preparing for a Study</b>	<b>62</b>
Study Design	62
Developing a Protocol	70
Case Report Forms (CRFs)	79
<b>Chapter 8: Clinical Investigators</b>	<b>88</b>
Investigators and Their Responsibilities	88
Evaluating and Selecting Investigators	92
Locating Potential Investigators	94
<b>Chapter 9: Study Initiation</b>	<b>102</b>
Study Initiation Documents	102
Financial Disclosure	103
The Investigator Meeting	105
Study Initiation Meetings	113
Investigator Study Files	116
Grants and Contracts	118
<b>Chapter 10: Study Monitoring</b>	<b>124</b>
The Game Plan for Monitoring	124
Preparing for a Monitoring Visit	128
Site Monitoring Visits	130
Confidentiality	143
The End of the Visit	144
Monitoring Visit Reports	145
Conclusion	146

<b>Chapter 11: Adverse Events and Safety Monitoring</b> .....	<b>149</b>
Regulations .....	149
Adverse Events (AEs) on Marketed Products .....	152
Adverse Events (AEs) in Clinical Trials .....	153
Investigator Reporting Responsibilities .....	156
Sponsor Responsibilities .....	157
Differences Between Clinical Studies and Clinical Practice .....	157
Common Reporting Problems .....	160
<b>Chapter 12: Recruitment, Retention, and Compliance</b> .....	<b>162</b>
Recruitment of Study Subjects .....	162
Retention of Study Subjects .....	173
Subject Compliance .....	178
<b>Chapter 13: Study Closeout</b> .....	<b>185</b>
Reasons for Study Closeout .....	185
Closeout Procedures .....	187
<b>Chapter 14: Audits</b> .....	<b>191</b>
Sponsor Audits of Investigative Sites .....	191
IRB Audits of Investigative Sites .....	194
FDA Audits .....	194
<b>Chapter 15: Errors, Misconduct, and Fraud</b> .....	<b>203</b>
Definitions .....	203
Errors .....	204
Misconduct .....	206
Fraud .....	208
Conclusion .....	214
<b>Chapter 16: The Future for CRAs</b> .....	<b>215</b>
Shifting Responsibilities .....	216
Coming Full Circle .....	217
Improving Relationships with Investigators .....	218
Impact of Technology .....	218
Conclusion .....	219
<b>Afterword</b> .....	<b>221</b>
<b>Appendix A: Resources</b> .....	<b>222</b>
<b>Appendix B: Hints and Tips</b> .....	<b>227</b>
<b>Appendix C: Sample Forms, Checklists, and Logs</b> .....	<b>238</b>
<b>Appendix D: Job Descriptions and Academic Programs</b> .....	<b>262</b>

<b>Appendix E: ICH–FDA Comparison</b> .....	<b>270</b>
<b>Appendix F: Harmonized Tripartite Guidelines for Good Clinical Practice</b> .....	<b>274</b>
<b>Appendix G: Code of Federal Regulations</b> .....	<b>327</b>
21 CFR 50 .....	327
21 CFR 54 .....	347
21 CFR 56 .....	353
21 CFR 312 .....	369
FDA Form 1572 .....	435
<b>About CenterWatch</b> .....	<b>437</b>
<b>About the Authors</b> .....	<b>443</b>